-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 20, Pioneer Pharmaceuticals entered into an exclusive license agreement with Gensun Biopharma Inc. ("Gensun"), a controlling subsidiary of Zee-Jun Pharmaceuticals.
Under the agreement, Pioneer Pharmaceuticals will receive exclusive clinical development and commercialization licenses from Gensun's PD-L1/TGF-beta dual-target antibody GS19 in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan).
under the terms of the agreement, Gensun will receive a total of up to $23 million, including down payments and milestone payments based on the registration and clinical development phases.
addition, Pioneer Pharmaceuticals will pay Gensun a percentage of its royalties based on GS19's annual net sales in Greater China.
GS19 is a dual-target antibody for PD-L1 and TGF-beta R2 with highly active inhibitions of both PD-L1 and TGF-beta R2, and Gensun owns the global intellectual property rights in the drug.
genetically modified to reduce degradation or fragmentation of the drug in CHO cell expression proteins, make it easier to commercialize production, and has the potential to be the best-in-class drug.
: Pioneer Pharmaceuticals and Gensun Biopharma announce exclusive licensing partnership for dual-target antibody PD-L1 / TGF-beta. Retrieved Aug 21, 2020, Gensun, a subsidiary of Zee-Yuan Pharmaceuticals, and Pioneer Pharmaceuticals announced an exclusive license agreement for PD-L1/TGF-beta dual-target antibodies in Greater China. Retrieved Aug 21,2020, from.
